Non-profit organisations the EspeRare Foundation, based in Switzerland, and US-based n-Lorem Foundation on Wednesday announced a strategic collaboration to expand access in Europe to n-Lorem's antisense oligonucleotide (ASO) therapies for patients with rare genetic diseases.

The collaboration aims to address the regulatory, operational, and diagnostic barriers that limit access to personalised genetic medicines outside the United States. The partnership will initially focus on pursuing treatment of a small number of nano-rare patients in Switzerland, with the goal of establishing a scalable model to support subsequent expansion across the European Union.

EspeRare will work with n-Lorem to support the identification of European patients who may benefit from n-Lorem's individualised ASO therapies that are already being used to treat nano-rare patients safely under FDA authorisation and to help enable the regulatory and clinical pathways required for treatment within Swiss and European academic medical centres.